Find a Scientist
Fredric Manfredsson, PhD
Fredric Manfredsson, PhD, is an associate professor in the Department of Neurobiology at Barrow Neurological Institute.
Dr. Manfredsson’s expertise includes microbiology and virology, with a special interest in gene therapy for Parkinson’s disease and other neurodegenerative diseases. He is a member of the American Society for Gene & Cell Therapy, The American Society for Neural Therapy and Repair, and the Society for Neuroscience.
Dr. Manfredsson earned his doctorate degree in neuroscience from the University of Florida in Gainesville, where he also completed a postdoctoral fellowship in neuroscience.
Dr. Manfredsson’s research has multiple focuses. One aspect is to better understand the role of the protein alpha-synuclein in both healthy cells and those affected by Parkinson’s disease. His research also emphasizes understanding the symptomology of the disease, with a focus on the treatment of levodopa-induced dyskinesia and nonmotor symptoms experienced by nearly all patients with Parkinson’s disease.
- Postdoctoral Fellowship, University of Florida, Department of Neuroscience, 2006-2010
- PhD, University of Florida, Graduate Program in Biomedical Sciences, Neuroscience, 2006
- BS, Arizona State University, Microbiology, 1999
- President, American Society for Neural Therapy and Repair, 2018-2020
- Fellow, American Society for Neural Therapy and Repair, 2015-Present
- Cover Image, Molecular Therapy, June 2009, March 2015
- Julius Axelrod Travel Award, Society for Neuroscience, 2011
- Alumni Fellowship, University of Florida, 2001-2005
- American Society for Gene & Cell Therapy
- The American Society for Neural Therapy and Repair
- Society for Neuroscience
Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus.
Date: 01/2020
Authors: Seong Su Kang, Xia Liu, Eun Hee Ahn, Jie Xiang, Fredric P Manfredsson, Xifei Yang, Hongbo R Luo, L Cameron Liles, David Weinshenker, Keqiang Ye
Fredric Manfredsson, PhD
Fredric Manfredsson, PhD, is an associate professor in the Department of Neurobiology at Barrow Neurological Institute.
Dr. Manfredsson’s expertise includes microbiology and virology, with a special interest in gene therapy for Parkinson’s disease and other neurodegenerative diseases. He is a member of the American Society for Gene & Cell Therapy, The American Society for Neural Therapy and Repair, and the Society for Neuroscience.
Dr. Manfredsson earned his doctorate degree in neuroscience from the University of Florida in Gainesville, where he also completed a postdoctoral fellowship in neuroscience.
Dr. Manfredsson’s research has multiple focuses. One aspect is to better understand the role of the protein alpha-synuclein in both healthy cells and those affected by Parkinson’s disease. His research also emphasizes understanding the symptomology of the disease, with a focus on the treatment of levodopa-induced dyskinesia and nonmotor symptoms experienced by nearly all patients with Parkinson’s disease.
- Postdoctoral Fellowship, University of Florida, Department of Neuroscience, 2006-2010
- PhD, University of Florida, Graduate Program in Biomedical Sciences, Neuroscience, 2006
- BS, Arizona State University, Microbiology, 1999
- President, American Society for Neural Therapy and Repair, 2018-2020
- Fellow, American Society for Neural Therapy and Repair, 2015-Present
- Cover Image, Molecular Therapy, June 2009, March 2015
- Julius Axelrod Travel Award, Society for Neuroscience, 2011
- Alumni Fellowship, University of Florida, 2001-2005
- American Society for Gene & Cell Therapy
- The American Society for Neural Therapy and Repair
- Society for Neuroscience
Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus.
Date: 01/2020
Authors: Seong Su Kang, Xia Liu, Eun Hee Ahn, Jie Xiang, Fredric P Manfredsson, Xifei Yang, Hongbo R Luo, L Cameron Liles, David Weinshenker, Keqiang Ye